Search Icon
Search Icon
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Abortion Drugs

Peer-Reviewed Article Debunks “Abortion Drugs Are Safer Than Tylenol” Claim

The decades-long claim, promoted by the abortion lobby, is a faulty comparison not backed by science

 

Washington D.C.—The Charlotte Lozier Institute (CLI) released a new pivotal peer-reviewed article published in the journal BioTech. This article challenges and disproves the baseless claim that “abortion drugs are safer than Tylenol” because it lacks scientific credibility and evidence. It examines the prolific claim that has been a heavily relied upon talking point for the abortion lobby.

The new research exposes the claim’s origins and highlights the abortion lobby’s ignorance of the FDA’s established drug safety communication standards. Comparisons between the two drugs combine unrelated data, ignoring their distinct purposes, risks and contexts. This oversimplification led to the creation of a catchy phrase aimed at reducing abortion drug regulations and minimizing concerns from women considering an abortion.

Key Findings:

  • Flawed methodology: To validate the claim, there must be a controlled, scientifically appropriate study comparing abortion drugs to Tylenol. No such study exists, and it would be impossible to do so because these drugs are used for entirely different purposes.
  • Overlooked risks: The FDA assesses drug safety based on a range of factors, not just death rates. The comparison ignores serious adverse events of abortion drugs, such as sepsis and hemorrhage.
  • Context misrepresentation: While Tylenol-related deaths often result from misuse in a much larger user base, deaths from abortion drugs occur under prescribed use.

Cameron Louttit, Ph.D., director of life sciences at CLI and author of the article, said:

“For years now, the abortion lobby’s claim that abortion drugs are ‘safer than Tylenol’ has dominated public discussion, propelled by the illusion of scientific consensus. However, no such support exists. This baseless claim, repeated by medical societies, politicians, media pundits and researchers, has profoundly influenced public opinion and policy. But as this paper details, those spreading it lack the evidence they routinely claim.”

To learn more, read the peer-reviewed article in its entirety HERE.

 

Charlotte Lozier Institute was launched in 2011 as the education and research arm of Susan B. Anthony Pro-Life America. CLI is a hub for research and public policy analysis on some of the most pressing issues facing the United States and nations around the world. The Institute is named for a feminist physician known for her commitment to the sanctity of human life and equal career and educational opportunities for women.

###

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification.

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

Ultrasound image showing the side profile of a human baby

Inside The Government Decision That Opened Up Abortion Pill Floodgates

charlotte-lozier-institute Charlotte Lozier Institute
October 6, 2026
A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined.

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image